Literature DB >> 28401582

Histological features of malignancy correlate with growth patterns and patient outcome in lung adenocarcinoma.

Johanna M Mäkinen1,2, Kirsi Laitakari3, Shirley Johnson3, Riitta Mäkitaro3, Risto Bloigu4, Paavo Pääkkö5, Elisa Lappi-Blanco1,5, Riitta Kaarteenaho3,6.   

Abstract

AIMS: Until the launch of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society adenocarcinoma classification in 2011, there were no uniform histological grading criteria for pulmonary adenocarcinomas. The current classification highlights the prognostic importance of the various histological growth patterns observed in these morphologically heterogeneous neoplasias. In this study, we aimed to evaluate the classic histological parameters of malignancy in correlation with the growth patterns and patient outcomes in a series of 112 surgically operated stage I-IV lung adenocarcinomas. METHODS AND
RESULTS: Architectural growth pattern analysis was performed according to the current adenocarcinoma classification. Histological features including, for example, nuclear atypia, mitotic activity, tumour necrosis, and different patterns of invasion were assessed and correlated statistically with the architecture and the clinical data. A solid predominant histology was associated with increased levels of atypia (P = 0.027), mitotic activity (P < 0.001), necrosis (P < 0.001), and lymphovascular invasion (P = 0.001), and a non-predominant solid pattern was associated with intra-alveolar tumour spread (P = 0.004). The presence of a non-predominant lepidic tumour component showed inverse correlations with atypia (P = 0.002), mitotic rate (P = 0.009), and tumour necrosis (P < 0.001). Tumour size (P < 0.001), mitotic activity (P = 0.019), tumour necrosis (P = 0.002), lymphovascular invasion (P = 0.001) and visceral pleural involvement (P = 0.001) were all associated with reduced disease-specific survival.
CONCLUSIONS: The classic histological features of malignancy correlate with tumour architecture and patient outcome, confirming the prognostic value of the growth pattern analysis and questioning the need for a parallel grading system in pulmonary adenocarcinoma.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  growth patterns; histology; lung adenocarcinoma; lung cancer; prognosis; smoking

Mesh:

Year:  2017        PMID: 28401582     DOI: 10.1111/his.13236

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Low-depth whole genome sequencing reveals copy number variations associated with higher pathologic grading and more aggressive subtypes of lung non-mucinous adenocarcinoma.

Authors:  Zheng Wang; Lin Zhang; Lei He; Di Cui; Chenglong Liu; Liangyu Yin; Min Zhang; Lei Jiang; Yuyan Gong; Wang Wu; Bi Liu; Xiaoyu Li; David S Cram; Dongge Liu
Journal:  Chin J Cancer Res       Date:  2020-06       Impact factor: 5.087

2.  Use of Computed Tomography-Guided Percutaneous Biopsy of Invasive Non-Mucinous Lung Adenocarcinoma to Predict the Degree of Histological Differentiation.

Authors:  Dehao Liu; Lichun Chen; Xiaoping Wang; Yikai Lin; Jianwei Gu
Journal:  Clin Med Insights Oncol       Date:  2022-06-07

3.  A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.

Authors:  Andre L Moreira; Paolo S S Ocampo; Yuhe Xia; Hua Zhong; Prudence A Russell; Yuko Minami; Wendy A Cooper; Akihiko Yoshida; Lukas Bubendorf; Mauro Papotti; Giuseppe Pelosi; Fernando Lopez-Rios; Keiko Kunitoki; Dana Ferrari-Light; Lynette M Sholl; Mary Beth Beasley; Alain Borczuk; Johan Botling; Elisabeth Brambilla; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Sanja Dacic; Deepali Jain; Fred R Hirsch; David Hwang; Sylvie Lantuejoul; Dongmei Lin; John W Longshore; Noriko Motoi; Masayuki Noguchi; Claudia Poleri; Natasha Rekhtman; Ming-Sound Tsao; Erik Thunnissen; William D Travis; Yasushi Yatabe; Anja C Roden; Jillian B Daigneault; Ignacio I Wistuba; Keith M Kerr; Harvey Pass; Andrew G Nicholson; Mari Mino-Kenudson
Journal:  J Thorac Oncol       Date:  2020-06-17       Impact factor: 15.609

4.  Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar-predominant lung adenocarcinoma.

Authors:  Hyun Woo Jeon; Young-Du Kim; Sung Bo Sim; Mi Hyoung Moon
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

5.  Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma.

Authors:  Hyun Woo Jeon; Young-Du Kim; Sung Bo Sim; Mi Hyoung Moon
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

6.  Correlation between clinicopathological characteristics of lung adenocarcinoma and the risk of venous thromboembolism.

Authors:  Yuan Zhang; Zhongyue Shi; Jiawen Yi; Jin Zhao; Shu Zhang; Wei Feng; Min Zhu; Bin Hu; Yuhui Zhang
Journal:  Thorac Cancer       Date:  2021-12-04       Impact factor: 3.500

7.  Clinicopathological predictors of survival in resected primary lung adenocarcinoma.

Authors:  Hiral Jhala; Leanne Harling; Alberto Rodrigo; Daisuke Nonaka; Emma Mclean; Wen Ng; Lawrence Okiror; Andrea Bille
Journal:  J Clin Pathol       Date:  2021-04-07       Impact factor: 4.463

8.  Comparison of clinical results between high grade patterns in stage I lung adenocarcinoma.

Authors:  Hyun Woo Jeon; Young-Du Kim; Sung Bo Sim; Mi Hyoung Moon
Journal:  Thorac Cancer       Date:  2022-07-12       Impact factor: 3.223

9.  A predictive nomogram for lymph node metastasis in part-solid invasive lung adenocarcinoma: A complement to the IASLC novel grading system.

Authors:  Zhaoming Gao; Xiaofei Wang; Tao Zuo; Mengzhe Zhang; Zhenfa Zhang
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

10.  Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients.

Authors:  Di-Han Liu; Zheng-Hao Ye; Si Chen; Xue-Song Sun; Jing-Yu Hou; Ze-Rui Zhao; Hao Long
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-28       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.